Nonetheless, our findings guide researchers to focus on issues raised by BRCA1/2 PV/LPV carriers that may pose as barriers in maximizing their cancer risk management options that arise with the knowledge of their BRCA1/2 status. The gene discussed is BRCA1; the disease is cancer.